Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental HIV treatments news

Show

From To
Tenofovir alafenamide equally effective but safer for kidneys and bones than current formulation

Tenofovir alafenamide (TAF), a new formulation that has lower concentrations in the blood but reaches higher levels in cells, is as effective as the older version, tenofovir disoproxil

Published
27 February 2015
By
Liz Highleyman
48-week analysis of investigational HIV-1 attachment inhibitor paves way for Phase III trial initiation

Phase III trial now underway for novel therapy for heavily treatment-experienced HIV-1 patients. Binding directly to the HIV virus, BMS-663068 is the first investigational antiretroviral designed to prevent initial viral attachment to host CD4+ T cells and entry into host immune cells. Phase III trial now underway for novel therapy for heavily treatment-experienced HIV-1 patients Binding directly to the HIV virus, BMS-663068 is the first investigational antiretroviral designed to prevent initial viral attachment to host CD4+ T cells and entry into host immune cells PRINCETON, N.J., February 25, 2015--Bristol-Myers Squibb Company (NYSE:BMY) today announced data...

Published
26 February 2015
From
Bristol Myers Squibb press release
HIV maturation inhibitor BMS-955176 looks promising in early study

A second-generation HIV maturation inhibitor, BMS-955176, demonstrated good safety and high potency, including activity against viral strains that were not susceptible to an earlier drug in this class,

Published
26 February 2015
By
Liz Highleyman
Experimental AIDS Drug Stirs Talk Of Vaccine 'Alternative'

For more than three decades, scientists have tried unsuccessfully to develop an effective vaccine for HIV, the virus that causes AIDS. But now researchers say they have created an experimental drug that may function as a sort of "alternative" vaccine for the virus. The experimental drug, a protein known as eCD4-IG, blocks infection by keeping the virus from binding to the immune cells that are the virus's target. In tests on monkeys, the drug "candidate" proved to be extremely effective at blocking infection--even with the most virulent strains of HIV and its simian counterpart, SIV.

Published
19 February 2015
From
Huffington Post
CytoDyn Concludes Phase 2b Study With 98% Success With 4 Weeks of Monotherapy

CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with human immunodeficiency virus (HIV), today announced that it had concluded its Phase 2b treatment substitution study and reported 39 patients out of 40 participating in the study passed 4 weeks of monotherapy with PRO 140.

Published
05 February 2015
From
CytoDyn press release
Researchers identify key mechanisms underlying HIV-associated cognitive disorders

New findings, published today by researchers at the University of California, San Diego School of Medicine, open the door to the development of new therapies to block or decrease cognitive decline due to HIV-associated neurocognitive disorders, estimated to affect 10 to 50 percent of aging HIV sufferers to some degree.

Published
04 February 2015
From
Medical Xpress
Treatment of the First HIV Positive Patient in ABIVAX's Phase IIa Clinical Trial With ABX464

ABX464 inhibits the biogenesis of viral RNA required for the replication of the HIV virus, a mechanism of action never before explored. ABX464 could be administered less frequently and for shorter periods than current HIV treatments due to its long lasting impact on viral load

Published
02 February 2015
From
ABIVAX press release
PREZCOBIX™ (darunavir/cobicistat) approved in the U.S. for the treatment of adults living with HIV-1

Combined fixed-dose tablet of darunavir and cobicistat can help reduce number of pills in a combination antiretroviral treatment regimen.

Published
30 January 2015
From
Janssen press release
U.S. Food and Drug Administration approves Bristol-Myers Squibb’s Evotaz™ (atazanavir and cobicistat) for the treatment of HIV-1 infection in adults

Evotaz is coformulated to be one pill, once-daily, combining the protease inhibitor atazanavir, which is marketed as Reyataz (atazanavir 200 mg/300 mg) capsules, and cobicistat, a pharmacokinetic enhancer marketed by Gilead Sciences, Inc.

Published
30 January 2015
From
Bristol-Myers Squibb press release
Merck (MRK) Receives Positive CHMP Opinion for Dutrebis as HIV 1 Treatment

On 22 January 2015, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Dutrebis, 150 mg lamivudine/300 mg raltegravir, film-coated tablet intended for the treatment of human immunodeficiency virus (HIV 1) infection in adults, adolescents, and children.

Published
26 January 2015
From
Street Insider
← First12345...81Next →

Filter by country